1. Home /
    2. Altai Protocol Library /
  2. New indication: Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New indication: Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

New indication: Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Study:
  • Multicenter, open-label, phase 1/2 trial
  • Cisplatin ineligible, local advanced/metastatic urothelial carcinoma
  • Enfortumab vedotin + pembrolizumab q21 (n=45)
Efficacy:
  • CRR: 15.6% [7 of 45 pts]
  • ORR: 73.3% [33 of 45 pts]
  • mDOR: 25.6 mos [8.28-NR]
  • mPFS: 12.3 mos [7.98-NR]
  • mOS: 26.1 mos [15.74-NR]
Safety:
  • Grade≥3AEs: Lipase increased (17.8%), maculopapular rash (11.1%), fatigue (11.1%), peripheral sensory neuropathy (4.4%)

J Clin Oncol 2023 41:1, 22-31

Hoimes J.C et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

http://doi.org/10.1200/JCO.22.01643

Reviewed by Elvin CHALABİYEV, MD on MAY 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More